KEYNOTE-181, a phase III clinical trial, showed that pembrolizumab could prolong OS among EC patients with a PD-L1 CPS ≥ 10 and patients with ESCC compared with chemotherapy. Here, CD274 is linked to esophageal squamous cell carcinoma.